Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
The Institute of Cancer Research
Headquarters: London, United Kingdom
Website: http://www.icr.ac.uk
Year Founded: 1909
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Aug 2, 2024
Distillery Therapeutics
Inhibiting NBS1 lactylation for chemotherapy resistance
BioCentury | Oct 20, 2023
Discovery & Translation
Targeted protein degrader design insights; plus Long COVID, obesity and more
BioCentury’s roundup of translational innovations
BioCentury | May 27, 2020
Emerging Company Profile
Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation
Versant-built start-up finds targets, compounds for protein degradation via structural biology and proteomics
BioCentury | Feb 29, 2020
Translation in Brief
Genentech finds non-exhausted antitumor T cell source in blood, plus updates on Penn and Chordoma Foundation-Mark Foundation
BioCentury’s roundup of preclinical news
BioCentury | Oct 16, 2019
Company News
AI play Healx raises $56M to repurpose drugs for rare disease
How Healx is tackling rare diseases using AI and input from patient groups
BioCentury | Oct 11, 2019
Preclinical News
Oct. 10 Preclinical Quick Takes: Merck-Prokaryotics Inc.-Princeton ID new antibiotic class; plus NIH, Owkin, Genentech and ICR
BioCentury | Jun 3, 2019
Clinical News
June 3 ASCO Quick Takes: ORR of 32% for Celgene's iberdomide in MM; plus Five Prime, Iovance and more
BioCentury | May 31, 2019
Targets & Mechanisms
Targeting cancer evolution offers a way to foil drug resistance
Solutions to cancer drug resistance could come from new understanding about tumor evolution and advances in liquid biopsies.
Items per page:
1 - 10 of 130